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Epigenetic mechanisms play a crucial role in regulating gene expression. The main
mechanisms involve methylation of DNA and covalent modifications of histones by
methylation, acetylation, phosphorylation, or ubiquitination. The complex interplay of
different epigenetic mechanisms is mediated by enzymes acting in the nucleus.
Modifications in DNA methylation are performed mainly by DNA methyltransferases
(DNMTs) and ten-eleven translocation (TET) proteins, while a plethora of enzymes,
such as histone acetyltransferases (HATs), histone deacetylases (HDACs), histone
methyltransferases (HMTs), and histone demethylases (HDMs) regulate covalent histone
modifications. In many diseases, such as cancer, the epigenetic regulatory system is often
disturbed. Vitamin D interacts with the epigenome on multiple levels. Firstly, critical genes
in the vitamin D signaling system, such as those coding for vitamin D receptor (VDR) and
the enzymes 25-hydroxylase (CYP2R1), 1α-hydroxylase (CYP27B1), and 24-hydroxylase
(CYP24A1) have large CpG islands in their promoter regions and therefore can be silenced
by DNA methylation. Secondly, VDR protein physically interacts with coactivator and
corepressor proteins, which in turn are in contact with chromatin modifiers, such as HATs,
HDACs, HMTs, and with chromatin remodelers. Thirdly, a number of genes encoding for
chromatin modifiers and remodelers, such as HDMs of the Jumonji C (JmjC)-domain
containing proteins and lysine-specific demethylase (LSD) families are primary targets
of VDR and its ligands. Finally, there is evidence that certain VDR ligands have DNA
demethylating effects. In this review we will discuss regulation of the vitamin D system
by epigenetic modifications and how vitamin D contributes to the maintenance of the
epigenome, and evaluate its impact in health and disease.
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INTRODUCTION
The role of vitamin D in regulating gene expression has become
increasingly evident since the discovery of the transcription fac-
tor vitamin D receptor (VDR), a member of the steroid nuclear
receptor superfamily. The effect of liganded VDR depends on
the epigenetic landscape of the target gene. Genome wide anal-
ysis in the human leukemia cell line THP-1 showed that VDR
binds mainly at loci of open chromatin. Upon treatment with
the VDR ligand 1,25-dihydroxyvitamin D3 (1,25-D3), chromatin
accessibility further increases in more than 30% of these loci
(Seuter et al., 2013). The mechanism of action of the liganded
VDR is dependent on binding and action of histone acetyltrans-
ferases (HATs) and histone methyltransferases (HMTs). It has
been shown that co-treatment of cells with 1,25-D3, and his-
tone deacetylase or DNA methyltransferase inhibitors often have
synergistic effects (Pan et al., 2010).
Many common diseases have both genetic and epigenetic
components, which communicate in an intricate and multilay-
ered manner. Currently, it is not clear to what extent epigenetic
alterations contribute to onset and progress of common dis-
eases, such as cancer. Epigenetics refers to processes that alter
gene activity without changing the DNA sequence. They play an
important role in regulating key processes during development,
including embryonic developmental events, gene imprinting, and
inactivation of chromosome X in females (Bird, 2002; Meissner
et al., 2008; Tsai and Baylin, 2011). Maintenance of normal func-
tioning of these biological processes is dependent on the intricate
interaction between several epigenetic mechanisms, such as DNA
methylation, histonemodifications, and non-coding RNAs (Jones
and Baylin, 2007). Therefore, at a given promoter the marks
arising from DNA methylation and histone modifications deter-
mine whether the chromatin is in an open (active) or a closed
(repressed) state. Deregulation of the epigenetic mechanisms can
lead to aberrant DNA methylation patterns and chromatin archi-
tecture, which is a common feature in cancer (Baylin and Jones,
2011; Tsai and Baylin, 2011; Helin and Dhanak, 2013).
EPIGENETIC CHANGES MEDIATED BY THE VITAMIN D
RECEPTOR AND ITS LIGANDS
The effect of nutrition on the methylation equilibrium of the
genome is already accepted as one of the mechanisms preventing
either promoter hyper- or global hypomethylation. Several nutri-
ents are renowned for their impact on DNA methylation, such as
folic acid, vitamin B, green tea, and alcohol (Arasaradnam et al.,
2008). The effect of vitamin D is currently under debate.
Primary epigenetic effects of vitamin D are linked to histone
modifications, mainly acetylation. The VDR/RXR dimer interacts
with HATs to induce transcriptional activation (Karlic and Varga,
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2011). Several studies have suggested that vitamin D may affect
also DNAmethylation. A recent study associated severe vitamin D
deficiency with methylation changes in leukocyte DNA, although
the observed differences were relatively small (Zhu et al., 2013).
This study suggested that subjects with vitamin D deficiency were
more likely to show reduced synthesis and increased catabolism
of active vitamin D. Whether this was the cause of the vitamin
D deficiency or the consequence thereof is not clear and needs
further studies.
EFFECT OF VITAMIN D ON DNA METHYLATION
DNA methylation is the most extensively studied epigenetic
mark (Esteller, 2008). In humans, DNA methylation occurs on
cytosines followed by guanine (CpG) (Bird, 1980; Gruenbaum
et al., 1981). Regions of DNA enriched in CpG clusters form
CpG islands (CGI) (Wang and Leung, 2004). DNA methylation
is necessary for regulating and orchestrating key biological pro-
cesses, including cell cycle, differentiation, as well as genomic
imprinting (Feinberg et al., 2002; Reik and Lewis, 2005; Jones
and Baylin, 2007). DNA hypermethylation is mainly found in
intergenic regions and repetitive genomic sequences to maintain
these in a transcriptionally inactive chromatin state (Herman and
Baylin, 2003).
DNA methyltransferases (DNMTs) mediate DNA methylation
(Robertson, 2005). DNMT1 encodes for a maintenance methyl-
transferase, whereas DNTM3A/3B encode for de novo methyl-
transferases, which are pivotal to maintain and establish genomic
methylation (Okano et al., 1998, 1999; Jin and Robertson, 2013).
However, in vivo studies suggest that all three DNMTs might
exert both de novo and maintenance functions (Rhee et al., 2000,
2002; Kim et al., 2002; Esteller, 2007a). Recently, a new group of
enzymes that induce active demethylation of the DNAwas discov-
ered, the ten-eleven translocation (TET) enzyme family, which
plays an important role both in development and tumorigenesis
(Kriaucionis and Heintz, 2009; Ficz et al., 2011; Williams et al.,
2011; Yamaguchi et al., 2012; Hackett et al., 2013).
Alterations in the cancer epigenome are generally associ-
ated with loss of global DNA methylation and gain of methy-
lation in specific gene promoters (Ting et al., 2006). Loss of
global methylation may lead to chromosomal instability (Eden
et al., 2003), loss of imprinting (Cui et al., 2003; Bjornsson
et al., 2007), and activation of transposable elements, thereby
leading to disturbances in the genome (Bestor, 2005; Esteller,
2008). Conversely, hypermethylation of promoter regions of
tumor suppressor genes (Greger et al., 1989; Sakai et al., 1991;
Esteller, 2008) leads to loss of expression of key genes affect-
ing pathways involved in maintenance of cellular functions,
including cell cycle, apoptosis, and DNA repair (Esteller, 2007b).
Several bona fide tumor suppressor genes are silenced by pro-
moter hypermethylation in tumors. For instance, hypermethy-
lation of the promoter of the DNA repair gene hMLH1 is
associated with early stages of endometrial and colon can-
cer, and microsatellite instability phenotype (Esteller et al.,
1999). Epigenetically mediated silencing of cyclin-dependent
kinase inhibitor 2A, which is crucial for control of cell cycle
has been reported in several cancers (Brock et al., 2008; Liau
et al., 2014). Additionally, pathways regulated by microRNAs
have been associated with DNA hypermethylation-dependent
silencing (Saito et al., 2006).
Besides methylating cytosines, DNMTs may coordinate other
chromatin-mediated aspects of gene expression at sites of gene
promoters (Herman and Baylin, 2003). For example, hyper-
methylation of promoters of tumor suppressor genes is asso-
ciated with recruitment of proteins belonging to the methyl
CpG-binding domain (MBD) family, MeCP2, MBD1, MBD2,
MBD3, and MBD4 (Ballestar and Esteller, 2005). It has been
shown that MeCP2 represses transcription of methylated DNA
by recruiting histone deacetylases (HDACs), providing the first
evidence for interactions between DNA methylation and histone
modifications (Jones et al., 1998; Nan et al., 1998).
There is evidence that 1,25-D3 is able to induce DNA demethy-
lation, however, the mechanisms behind the effect of 1,25-D3
on DNA methylation are not clear. In most cases it is prob-
ably passive demethylation that happens over several cycles of
DNA replication. However, in some cases demethylation occurs
within 1–4 h, indicative of an active process (Doig et al., 2013).
The fact that vitamin D can alter methylation of DNA in the
promoter of certain genes is novel. Tapp and colleagues sug-
gested that in healthy subjects global, age-related CGI methyla-
tion of human rectal mucosa was influenced not only by gender,
folate availability, and selenium, but also by vitamin D sta-
tus (Tapp et al., 2013). The authors show negative association
between serum 25-D3 level and CGImethylation of the adenoma-
tous polyposis coli (APC) promoter region, a tumor suppressor
often inactive in colorectal cancer. Interestingly, they observed
a weak positive correlation of vitamin D level with methyla-
tion of LINE-1 (genomic long interspersed nuclear element-1),
a mammalian autonomous retrotransposon, increasing stability
of this region (Tapp et al., 2013). A recent study in colorectal
cancer patients investigating two Canadian populations (from
Newfoundland and Ontario) found that high dietary vitamin D
intake was associated with lower methylation of the two WNT
antagonists dickkopf 1 (DKK1) and WNT5A (Rawson et al.,
2012). This relationship became even more significant in females
in the Newfoundland population, while in the Ontario pop-
ulation the association between vitamin D intake and lower
methylation was observed only in early stage tumors, but not
in late stage tumors (Rawson et al., 2012). These data con-
fer further insights in the mechanisms regulating the tran-
scriptional activating effect of vitamin D on DKK1 expression
described in vitro (Aguilera et al., 2007; Pendas-Franco et al.,
2008).
Moreover, treatment of the triple negative breast cancer cell
line MDA-MB-231 with 1,25-D3 reduced DNA methylation of
the e-cadherin promoter (Lopes et al., 2012), while another
study showed that 1,25-D3 induced demethylation of the PDZ-
LIM domain-containing protein 2 promoter, leading to increased
expression (Vanoirbeek et al., 2014). In non-malignant and
malignant prostate epithelial cells, treatment with 1,25-D3 caused
clear changes in site-specific methylation of the p21 promoter, in
a cell line-specific manner (Doig et al., 2013).
An interesting interaction between vitamin D and DNA
methylation is induction of the expression of GADD45 (growth
arrest and DNA damage) protein by 1,25-D3 in several tumor
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cells (Jiang et al., 2003; Zhang et al., 2006; Bremmer et al., 2012).
GADD45A is one of the enzymes that promote epigenetic gene
activation by repair mediated DNA demethylation in Xenopus
laevis (Barreto et al., 2007).
In summary, alterations in DNA methylation lead to aberrant
gene expression and disruptions of genomic integrity, which con-
tribute to development and progression of diseases. Vitamin D
can regulate these processes; the mechanisms behind need further
investigations.
INTERACTIONS OF VITAMIN D WITH CHROMATIN MODULATORS AND
REMODELERS
Nuclear receptors, such as the VDR contain DNA-binding
domains that mediate binding to the DNA, presuming the DNA
is available and is not wound tightly around nucleosomes. The
chromatin context determines nuclear receptor binding and
determines which epigenetic modifications will occur thereafter.
Upon binding to their genomic response elements, nuclear hor-
mone receptors will then recruit different regulatory cofactor
complexes (Lee et al., 2001). The unliganded VDR is able to
bind also genomic DNA, where it usually forms complexes with
corepressor proteins that either exert HDAC activity, e.g., ALIEN
(Polly et al., 2000), or are associated with HDACs, such as NCOR1
and SMRT. The corepressors dissociate upon binding of 1,25-D3,
and are replaced by coactivator complexes.
The chromatin environment dictates gene activity throughout
the genome. Post-translational modifications of the N-terminal
tails of histone proteins allow nucleosomes to shift, the chro-
matin to relax, and genes to become activated. Histone mod-
ifications change in response to environmental stimuli (Meyer
et al., 2013). Histones are major protein components of chro-
matin that undergo post-translational modifications, including
acetylation of lysines, methylation of lysines and arginines, and
phosphorylation of serine and threonine residues (Esteller, 2008).
In epigenetically silenced genes, hypermethylation of CGIs is
often associated with loss of acetylation on histone 3 and 4 (H3
and H4), loss of methylation of lysine (K) 4 on H3 (H3K4), and
gain of methylation of K9 and K27 on H3 (H3K9 and H3K27)
(Esteller, 2008).
Histone acetylation generally correlates with transcriptional
activation (Hebbes et al., 1988; Kouzarides, 2007) and is
dependent on a dynamic interaction between histone acetyltrans-
ferases (HATs) and histone deacetylases (HDACs) (Marks et al.,
2001). The balance between the actions of these enzymes is crucial
in controlling gene expression, and governs several developmen-
tal processes and disease states (Haberland et al., 2009). Generally,
HATs are defined as activators of transcription, whereas HDACs
as transcription repressors (Parbin et al., 2014). In various cancer
types, including prostate, gastric, and breast cancers, overexpres-
sion of HDAC1 is often associated with poor clinical outcome
(Choi et al., 2001; Halkidou et al., 2004; Zhang et al., 2005). In
colorectal cancer patients HDAC1, 2, and 3 are overexpressed,
and high HDAC1 and 2 expression is linked with reduced patient
survival (Zhu et al., 2004; Wilson et al., 2006). Overexpression of
HDAC1 plays a crucial role in regulating proliferation by repress-
ing the expression of the cyclin-dependent kinase inhibitor p21
(Lagger et al., 2003). Additionally, silencing of HDAC4 leads to
re-expression of p21, which in turn induces cell growth arrest and
tumor growth inhibition, both in vitro and in vivo in a human
glioblastoma model (Mottet et al., 2009). In addition to classical
HDACs, another group of enzymes, the sirtuins (silent informa-
tion regulator 2 proteins) are involved in histone deacetylation
(Schwer and Verdin, 2008). Sirtuins have been linked tometabolic
disorders, cancer, aging, and also regulation of the circadian
rhythm (Guarente, 2006; Longo and Kennedy, 2006; Jung-Hynes
et al., 2010).
Many of the coactivators recruited by the VDR, including
p160 steroid receptor coactivator proteins (SRC1, 2, and 3), p300,
or CBP have lysine acetyltransferase activity (Figure 1). Indeed,
treatment of THP-1 cells with 1,25-D3 increased H3K27ac at
the promoter of several early VDR target genes (Seuter et al.,
2013). In genetic hypercalciuric stone forming rats inhibition
of bone morphogenetic protein 2 (BMP2) by 1,25-D3, seems to
involve H3 deacetylation and H3K9 di-methylation (Fu et al.,
2013).
In MDA-MB453 breast cancer cells 1,25-D3 treatment reg-
ulates expression of p21 through a mechanism involving both
histone acetylation and methylation, probably by dynamic
FIGURE 1 | Simplified illustration of a two-step coregulator model.
The VDR/RXR complex in absence of the 1,25-D3 may bind
corepressors that would lead/maintain gene repression, partly by
attracting histone deacetylases (HDACs). Upon ligand binding to the
VDR/RXR complex, corepressors are replaced by coactivators, which
include histone acetyltransferases (HATs). Acetylation of histones
(indicated by the green stars) enables chromatin relaxation and gene
transcription.
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chromatin looping from distal 1,25-D3 responsive elements to the
TSS of p21 (Saramäki et al., 2009).
Histone methylation can lead either to gene activation or
repression, depending on the histone site that is methylated, the
degree of methylation (e.g., mono-methylation, di-methylation,
or tri-methylation), amino acid residues affected, and their posi-
tion in the histone tail (Esteller, 2008). Methylation of his-
tones depends on a dynamic process arising from the actions
of methyltransferases (HMTs) and demethylases (HDMs) (Shi
and Whetstine, 2007; Mosammaparast and Shi, 2010; Greer and
Shi, 2012). So far, two protein families capable of demethylat-
ing lysines are known, the amine oxidases (Shi et al., 2004)
and jumonji C (JmjC)-domain-containing proteins (Cloos et al.,
2006; Tsukada et al., 2006). The first histone demethylase dis-
covered was the lysine-specific demethylase 1 (LSD1/KDM1A),
an amine oxidase, which demethylates H3K4me2/me1 (Table 1)
(Shi et al., 2004). High expression of KDM1A in various cancers,
including colorectal cancer, prostate cancer, and neuroblastomas
is associated with increased cancer recurrence and poor clini-
cal outcome (Kahl et al., 2006; Schulte et al., 2009; Ding et al.,
2013). Additionally, it has been shown that LSD1 is essential
for androgen and estrogen receptor-dependent gene activation
via H3K9me2/me1 demethylation (Metzger et al., 2005; Garcia-
Bassets et al., 2007; Perillo et al., 2008). There is a recipro-
cal regulatory effect between the activity of VDR and histone
demethylases. In the colon cancer cell line SW480-ADH 1,25-D3
increased the expression of the lysine-specific demethylase 1 and
2 (Pereira et al., 2012).
1,25-D3 treatment affected also the expression of a series of
different JmjC histone demethylases. The first identified member
of the JmjC family was KDM2A/JHDM1A (Tsukada et al., 2006).
Expression profiling data showed altered expression of KDM2A
and KDM2B in several tumors, however, it seems that their pro-
or antioncogenic functions are tissue-dependent (Frescas et al.,
2007, 2008; Pfau et al., 2008). 1,25-D3 inhibited the expres-
sion of several histone demethylases (e.g., KDM4A/4C/4D/5A/2B,
JMJD5/6, PLA2G4B), and induced the expression of others,
JARID2 and KDM5B (Pereira et al., 2012).Members of the KDM4
family catalyze tri-demethylation of H3K9 and/or H3K36 (Cloos
et al., 2006; Fodor et al., 2006; Klose et al., 2006; Whetstine
et al., 2006; Lin et al., 2008). H3K9me3 is a mark for hete-
rochromatin and demethylation of H3K9 is suggested to be linked
with chromosomal instability (Cloos et al., 2006). Inhibition of
expression of KDM4 family members by 1,25-D3 could thus
contribute to genome stability. Members of KDM5 cluster cat-
alyze demethylation of H3K4me3/me2, which is a mark for open
chromatin (Christensen et al., 2007; Iwase et al., 2007; Klose
et al., 2007; Tahiliani et al., 2007) and their upregulaton upon
1,25-D3 treatment might lead to gene repression (Pereira et al.,
2011). Overexpression of KDM5B has been reported in breast and
prostate cancers (Lu et al., 1999; Xiang et al., 2007). Deletion of
kdm5b inhibits tumor growth in a syngeneic mouse mammary
Table 1 | A simplified list of the members of the two classes of histone demethylases (mentioned in the manuscript).
Class of Histone Histone Histone Gene
histone demethylases demethylase family demethylase substrate expression
Amine oxidases KDM1 KDM1A
KDM1B
H3K4me2/me1
H3K9me2/me1
H3K4me2/me1
Repression
Activation
Repression
Jumonji C-domain-containing proteins KDM2 KDM2A H3K36me2/me1 Repression
KDM2B H3K4me3
H3K36me2/me1
KDM3 KDM3A H3K9me2/me1 Activation
KDM3B H3K9me3/me2/me1
KDM4 KDM4A
KDM4B
KDM4C
H3K9me3/me2
H3K36me3/me2
Activation
Repression
KDM4D H3K9me3/me2 Activation
KDM5 KDM5A H3K4me3/me2 Repression
KDM5B
KDM5C
KDM5D
KDM6 KDM6A H3K27me3/me2 Activation
KDM6B
PHF JHDM1D H3K9me2/me1
H3K27me2/me1
Activation
PHF8 H3K9me2/me1
Reviewed in Pedersen and Helin (2010), Greer and Shi (2012). The main histone demethylase families and submembers are indicated. Degree of methylation and site
of lysine residue are given. References for individual enzymes can be found throughout the text. H, Histone; K, lysine; me1, mono-methylation; me2, di-methylation;
me3, tri-methylation; KDM1A, lysine-specific demethylase 1A; JHDM1D, JmjC-domain-containing histone demethylation protein 1D; PHF, plant homeodomain finger
protein.
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tumor (Yamane et al., 2007), suggestive of its potential role in
tumor development. 1,25-D3 induced the expression of the his-
tone demethylase KDM6B as well, which is the only other known
enzyme, besides KDM6A that is able to demethylate H3K27me3,
a histone mark that correlates with gene repression. Furthermore,
the authors showed positive correlation between KDM6B and
VDR in 96 colon tumor patients, and inverse correlation of
KDM6B with SNAIL1, which is involved in epithelial to mes-
enchymal transition, indicating that probably the antiproliferative
role of 1,25-D3 via KDM6B upregulation might take place in vivo
(Pereira et al., 2011). Interestingly, treatment of SW480-ADH
cells with 1,25-D3 had no effect on global H3K27me3 levels, in
spite of KDM6B upregulation (Pereira et al., 2011, 2012). The
effect of 1,25-D3 on the expression of histone demethylases may
well be indirect and could be mediated by microRNAs (Padi et al.,
2013). KDM2A is one of the direct targets of microRNA-627.
1,25-D3-dependent upregulation of the microRNA-627 expres-
sion both in vitro, in the HT-29 colorectal cancer cells and in vivo,
in tumor xenografts, led to lower KDM2A levels (Padi et al.,
2013).
In different pathologies, the expression pattern of the nuclear
receptor cofactors is altered, compromising the effect of 1,25-D3
(Doig et al., 2013; Singh et al., 2013). The initial interactions
between VDR and coactivators are the seed for the assembly
of intricate multiprotein complexes that remodel the chromatin
structure, recruit the core transcriptional machinery, and induce
expression of 1,25-D3 target genes (Figure 1). Often, differences
in responsiveness to 1,25-D3 depend on the expression pattern
of the coregulators of VDR. In prostate cancer cells, the tem-
poral distribution of the nuclear corepressor NCOR1 at VDR
target genes is different in 1,25-D3 responsive cells compared with
unresponsive cells (Doig et al., 2013; Singh et al., 2013).
The liganded VDR is able both to transactivate and tran-
srepress target genes. The mechanisms of action are probably
different between transactivation and transrepression, and also
highly dependent on the motifs of the vitamin D response
elements. A highly complex mechanism regulates the ligand-
dependent repression of CYP27B1 (Kim et al., 2007a). CYP27B1
repression requires two epigenetic modifications: deacetylation
of histones and methylation of the CYP27B1 gene promoter and
exon regions. This is dependent on the presence of the VDR inter-
acting repressor (VDIR) and the chromatin remodeler Williams
Syndrome transcription factor. In the absence of 1,25-D3, VDIR
is bound directly to the E-box motifs in the negative VDRE and
recruits histone acetyltransferases to induce CYP27B1 gene tran-
scription. In the presence of 1,25-D3, VDIR acts as a scaffold for
the 1,25-D3-VDR complex to repress transcription of CYP27B1
through recruitment of HDAC2, DNMT1, and DNMT3B (Kim
et al., 2007a). It seems that VDIR and HDAC2 are involved
also in the 1,25-D3-dependent transrepression of the human
parathyroid hormone gene (Kim et al., 2007b). It is not clear,
whether this mechanism of transrepression by liganded VDR
also applies to other genes. In mesenchymal stem cells 1,25-D3
represses gene expression by binding to promoters with enhanced
H3K9Ac and H3K9me2 (Tan et al., 2009). Whether H3K9 acety-
lation/methylation enabled VDR binding or VDR binding caused
H3K9 acetylation, is not clear.
Proper orchestration of histonemodifications in crosstalk with
other chromatin regulators is crucial in maintaining the epige-
netic landscape and governing gene expression. Any disturbances
in these constellations may lead to aberrant gene expression.
Whether 1,25-D3 affects regulation of other chromatin modula-
tors as well, is not yet known.
REGULATION OF THE VITAMIN D SYSTEM
The vitamin D system has pleiotropic functions and regulates
approximately 3% of the human genome (Bouillon et al., 2008).
To maintain balance, a strict regulation of the vitamin D system
genes is of utmost importance. The main role of liganded VDR in
tissues not involved in calcium homeostasis is to control expres-
sion of genes that regulate cell proliferation, differentiation, and
apoptosis. One major limitation in the therapeutic exploitation of
these effects is the resistance of cancer cells to 1,25-D3. Epigenetic
corruption of VDR signaling is suggested to be one of the mech-
anisms that leads to reduced responsiveness to 1,25-D3 actions.
This can be caused by promoter methylation of key vitamin D
system genes or by skewed accumulation of VDR-associated co-
repressors, preferentially at promoters of anti-proliferative target
genes (Abedin et al., 2006).
Expression of the vitamin D degrading and metabolizing
enzymes is regulated through binding of 1,25-D3-liganded VDR
to vitamin D responsive elements (VDREs). However, the major
regulators of 1,25-D3 levels and signaling CYP2R1, CYP24A1,
CYP27B1, and VDR, “the vitamin D tool” genes, are prone to epi-
genetic regulation. CpG islands span the promoters of CYP2R1,
CYP24A1, and VDR, while a CpG island is located within the
CYP27B1 gene locus (Figure 2). Therefore, DNAmethylation and
histone modifications in these regions can change the chromatin
state from an open to closed conformation and lead to tran-
scriptional repression of these genes. Expression of vitamin D
tool genes becomes deregulated in various types of cancer, and
these changes may be partially attributed to epigenetic alterations
(reviewed in Hobaus et al., 2013). As early as 1984, Yoneda et al.
(1984) have shown that the histone acetyltransferase inhibitor
butyrate augments 1,25-D3 actions. Several studies confirmed
these findings (e.g., Rashid et al., 2001) and have suggested that
the action of butyrate could be through upregulation of VDR or
CYP27B1 expression (Gaschott and Stein, 2003). Whether this
effect is mediated by direct acetylation of the VDR or CYP27B1
promoters, has not been determined.
In this chapter we discuss evidence for epigenetic regulation
through DNA methylation of these genes in health and disease.
EPIGENETIC REGULATION OF THE VITAMIN D RECEPTOR
The VDR is a nuclear receptor mediating 1,25-D3 signaling. It is
expressed by at least 38 cell types in the human body (Norman
and Bouillon, 2010). In the absence of its ligand 1,25-D3, VDR
is mainly found in the cytoplasm (Nagpal et al., 2005). Upon lig-
and binding, VDR heterodimerizes with the retinoid X receptor
(RXR) and translocates to the nucleus, where it binds to vita-
min D responsive elements (VDREs) to regulate transcription
of 1,25-D3 target genes. This is achieved through recruitment of
coactivators or corepressors to the VDR-RXR complex bound to
DNA (Nagpal et al., 2005; Pike et al., 2012; Haussler et al., 2013;
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FIGURE 2 | Location of CpG islands in the promoter region of vitamin
D tools genes. VDR is located on 12q13.11 (chr12:48235320-48298814),
CYP2R1 on chromosome 11p15.2 (chr11:14899556-14913751), CYP24A1 on
chromosome 20q13.2 (chr20:52769988-52790516), and CYP27B1 on
12q14.1 (chr12:58156117-58160976). The locations of the CpG islands are
indicated (black bars) relative to start of the gene locus (not to TSS)
according to UCSC Genome Browser Homepage (GRCh37/hg19) (Karolchik
et al., 2014). Number of CpGs located within each island is stated. Two
vitamin D responsive elements (VDRE) are located in the proximal
CYP24A1 promoter region and one nVDRE is located in the CYP27B1
promoter region.
Pike and Meyer, 2013). As VDR is rarely mutated during car-
cinogenesis (Miller et al., 1997), the disturbance of the vitamin
D signaling and apparent 1,25-D3 insensitivity in cancer (Marik
et al., 2010) must be attributed to other alterations, which may
include epigenetic changes, such as promoter methylation.
The VDR gene is located on the long arm of chromosome 12
(12q13.11) and contains 4 potential promoter regions. Exons 1a,
1c, and 1d of the VDR are well conserved, while 1b, 1e, and 1f
show low homology (Halsall et al., 2007). Exon 1a appears to
contain a strong promoter, including several transcription fac-
tor binding sites (AP-2 and SP1). Transcription was reported to
originate also in exons 1d, 1e, and 1f, while translation starts in
exon 2 (Halsall et al., 2007). Marik and colleagues performed an
in silico analysis of the VDR gene sequence and reported three
CpG islands located in exon 1a spanning from −790 bp to 380 bp
relative to the TSS in exon 1a (Marik et al., 2010). According to
the UCSC Genome browser, however, only one large CpG island
spanning 892 bp in length is found in the VDR promoter region
(Gardiner-Garden and Frommer, 1987; Karolchik et al., 2014).
This discrepancy is likely due to the different search parameters
used for CpG island identification.
Epigenetic silencing of VDR was suggested to cause the slow
normalization of VDR levels in the parathyroid glands of uremic
rats after kidney transplantation (Lewin et al., 2002; Hofman-
Bang et al., 2012). However, sequencing of the VDR promoter
[−250 to 300 bp relative to exon 1 (43CpGs)] in normal and
uremic rats showed no difference between methylation patterns
(Hofman-Bang et al., 2012). Further, the authors reported that
methylation levels coincided with the negative control, thus show-
ing that promoter methylation does not play a role in regulating
VDR expression in the parathyroid glands.
In contrast, promoter methylation was reported to cause
repression of VDR gene expression in HIV infected T cells. In
normal T cells, activation or priming causes an upregulation of
VDR expression (Von Essen et al., 2010). In comparison, infection
of previously activated T cells with human immunodeficiency
virus (HIV) led to upregulation of DNMT3B, increased promoter
methylation of VDR (45–70%), and decreased VDR gene expres-
sion (Chandel et al., 2013). This downregulation of VDR could
be reversed upon treatment with 5-azacytidine (AZA) suggest-
ing that the decreased expression of VDR by HIV is, at least
partially, caused by DNA methylation (Chandel et al., 2013).
There is evidence for an inverse correlation between the vitamin
D status and infections, however, many trials failed to show a
protective effect of vitamin D (reviewed in Yamshchikov et al.,
2009). Thus, reduced sensitivity to vitamin D metabolites due to,
e.g., downregulation of VDR may account for inconclusive tri-
als. This is supported by a study investigating methylation of the
3′end of VDR in two South African groups revealing differences
with respect to ethnicity and tuberculosis status of the patients
(Andraos et al., 2011).
In breast tumors, methylation of exon 1a of the VDR gene was
significantly higher (65% of CpGs methylated) compared with
normal breast tissue (15% of CpGs methylated) (Marik et al.,
2010). In vitro, in breast cancer cell lines, three hypermethylated
regions in exon 1a became demethylated after treatment with
the DNMT1 inhibitor 5-aza-2′-deoxycytidine (DAC) and VDR
mRNA expression increased. These regions were in proximity to
the SP1 binding sites (approximately 790 bp from TSS), NFκB
binding sites (approximately −480 from TSS), and the exon 1a
TSS. Treatment with 1,25-D3 had no effect on methylation of
these regions (Marik et al., 2010). In other types of cancer, e.g., the
choriocarcinoma-derived trophoblast cell lines JEG-3 and JAR,
the VDR promoter was densely methylated (Novakovic et al.,
2009). In contrast, no methylation of the VDR promoter region
was observed in colon cancer cell lines, and treatment with DAC
did not increase gene expression (Habano et al., 2011; Höbaus
et al., 2013a). In parathyroid tumors the expression of VDR is
decreased (Gogusev et al., 1997; Carling et al., 2000), however, no
differences in DNA methylation of VDR were observed between
parathyroid tumors and healthy controls (Sulaiman et al., 2013).
Similar results were seen in parathyroid adenoma samples, which
showed decreased expression of VDR, but showed no promoter
methylation (Varshney et al., 2013).
Additionally, it has been suggested that expression of 5′ trun-
cated variants of VDR is linked to methylation of the VDR pro-
moter. These variants are predominantly found in breast cancer
compared with the full length variants expressed in normal breast
tissue. Treatment with DAC restored expression of the active
transcript variant of VDR in breast cancer cell lines, indicating
promoter methylation as cause of truncated protein expression
(Marik et al., 2010). The significance of these potentially untrans-
lated truncated variants remains to be investigated, however, as
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they are not found in normal breast tissue aberrant expression
of truncated isoforms may further disrupt vitamin D signaling in
tumor tissue.
A recent study suggested that in colorectal cancer metastases,
VDR becomes the target of the polycomb group protein enhancer
of zeste homolog 2 (EZH2) that mediates VDR downregulation
by H3K27 trimethylation in the VDR promoter (Lin et al., 2013).
The histone deacetylase HDAC3, one of the most frequently
upregulated genes in cancer, seems to inhibit VDR expression. In
two colorectal cancer cell lines, HCT116 and SW480 knock down
of HDAC3 increased VDR expression and restored sensitivity of
these cells to 1,25-D3 (Godman et al., 2008).
Taken together, there is evidence that in various diseases the
decreased tissue sensitivity to 1,25-D3 could have been caused by
the epigenetic silencing of the VDR.
EPIGENETIC REGULATION OF THE CYP2R1
CYP2R1 is a microsomal P450 enzyme, which hydroxylates both
vitamin D2 and D3 at position C-25 to form the circulating stor-
age form of vitamin D 25-D3. The promoter region of CYP2R1 is
located within a CpG island, which can be subjected to epigenetic
regulation. So far, only two studies investigated the promoter
methylation status of this gene. Genome wide association stud-
ies found increased CYP2R1 promoter methylation in leukocyte
DNA from individuals with severe vitamin D deficiency com-
pared with control group (Zhu et al., 2013). Further, methylation
levels of CYP2R1 promoter decreased within 12 months of vita-
min D supplementation in DNA extracted from serum of non-
Hispanic white American post-menopausal women aged ≥55
years (Zhu et al., 2013), indicating an effect of vitamin D supple-
mentation on CYP2R1 promoter methylation. These data indi-
cate that under low vitamin D serum levels, the promoter of
the major 25-hydroxylase CYP2R1 may become methylated, and
that event appears to be reversible upon exposure to increased
vitamin D.
EPIGENETIC REGULATION OF THE CYP27B1
CYP27B1 is an inner mitochondrial membrane P450 enzyme that
converts 25-D3 to its active form 1,25-D3. It is mainly expressed
in the proximal tubule of the kidneys, but it is also expressed
in many vitamin D target tissues, albeit at lower levels (Hendrix
et al., 2004). The CYP27B1 gene harbors a CpG island. However,
recent sequence updates (Ensembl 74, November 2013) shift the
CpG island from theCYP27B1 promoter region into the gene cod-
ing sequence (Flicek et al., 2014). This explains the differences
between the location of the CpG island depicted in Figure 2 and
the location of the CpG island described in literature. For simplic-
ity, statements on nVDRES and CpG island location below refer
to reports in the published articles and not to Figure 2.
The promoter region of CYP27B1 contains a negative VDRE
(nVDRE) located at around 500 bp, consisting of two E-box like
motifs (Murayama et al., 2004). This region is responsible for
1,25-D3-dependent transrepression, which seems to be achieved
through recruitment of both HDACs and DNMTs by VDR/RXR
to the promoter region of CYP27B1 (Takeyama and Kato, 2011).
For further details see subsection Interactions of Vitamin D with
Chromatin Modulators and Remodelers.
In cancer, expression of CYP27B1 is often downregulated. This
may be explained by increased methylation of the CpG island
located within CYP27B1. In the breast cancer cells MDA-MB-
231, CYP27B1 hypermethylation led to gene silencing, which
could be reversed by treatment with deoxyC (Shi et al., 2002). In
prostate cancer cell lines, combination of the DNMT1 inhibitor
DAC and the HDAC inhibitor TSA resulted in increased activ-
ity of CYP27B1 (Khorchide et al., 2005). In the choriocarcinoma
cell lines BeWo and JAR the promoter of CYP27B1 was densely
methylated (Novakovic et al., 2009). The CYP27B1 promoter was
hypermethylated (61%) in Non-Hodgkin’s lymphoma, but not
in benign follicular hyperplasia. Two out of four non-Hodgkin’s
lymphoma cell lines showed strong methylation of the CYP27B1
promoter. Interestingly, all four responded to DAC-TSA treat-
ments with upregulation of gene expression independent of the
methylation status of their CYP27B1 promoter, which may be
explained by other regions prone to methylation not investigated
in this study or by differences in silencing mechanisms (Shi et al.,
2007). Further, the methylation level ofCYP27B1was increased in
primary lymphoma and leukemia cells also compared with nor-
mal peripheral blood lymphocytes (Lagger et al., 2003; Wjst et al.,
2010).
Methylation of CYP27B1 in diseases might cause reduced local
activation of 25-D3 to 1,25-D3, thus reducing local 1,25-D3 levels
and restricting its functions.
EPIGENETIC REGULATION OF CYP24A1
The 1,25-dihydroxyvitamin D3 24-hydroxylase is an inner mito-
chondrial membrane P450 enzyme, which catalyzes both 25-D3
and 1,25-D3 (Kawashima et al., 1981; Pedersen et al., 1983; Sakaki
et al., 2000). Its primary site of expression are the kidneys, where
it plays a crucial role in regulating systemic vitamin D metabo-
lite levels, however, expression is found in many other vitamin D
target tissues.
The promoter of CYP24A1 is spanned by a CpG island making
it prone to regulation by DNA methylation. Several responsive
elements are located within this area, including two VDREs, a
vitamin stimulating element (VSE), and SP1 binding sites (see
Figure 2).
In healthy kidney, skeletal muscle, whole blood, brain, skin
fibroblasts, and sperm the CYP24A1 promoter is not methy-
lated (Novakovic et al., 2009), although the expression levels
are highly variable. In peripheral blood lymphocytes methyla-
tion of CYP24A1 was low (5%) (Wjst et al., 2010). Interestingly,
in full term human placenta 56.5% of the CYP24A1 promoter
is methylated. CYP24A1 methylation was also observed in the
placenta of the marmoset and mouse, however, at a lower
level.
In the choriocarcinoma cell lines JEG-3, BeWo, and JAR the
promoter of CYP24A1 was densely methylated and the methy-
lation level correlated inversely with the low gene expression
(Novakovic et al., 2009). Treatment of osteoblastic ROS cells
with 1,25-D3 did not induce CYP24A1 expression. Considering
the strong methylation of the CYP24A1 promoter region, epi-
genetic silencing of CYP24A1 may account for the unrespon-
siveness of this gene to 1,25-D3 (Ohyama et al., 2002). In the
human prostate cancer cell line PC3, methylation of the CYP24A1
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promoter reduced reporter gene expression in a methylation-
dependent manner (Luo et al., 2010). In prostate cancer cells,
the methylation status of CYP24A1 promoter inversely correlated
with gene expression. Demethylating agents restored CYP24A1
expression only in cell lines where the CYP24A1 promoter was
methylated prior to treatment (Luo et al., 2010). Only DNA
demethylation by DAC treatment permitted recruitment of VDR
to the CYP24A1 promoter (Luo et al., 2010). In patients, devel-
opment from benign toward malignant prostate lesions was
paralleled by increasing methylation levels of the CYP24A1 pro-
moter (Luo et al., 2010). Prostate tumor derived endothelial
cells (TDEC) expressed less CYP24A1 compared with endothe-
lial cells derived from normal cells or matrigel plugs, which may
be attributed to increased CYP24A1 promoter methylation in
TDECs (Johnson et al., 2010). We have shown recently that in
colon cancer cell lines DAC induced CYP24A1 expression in a
cell line-specific manner, independent of the methylation level of
the promoter. In these cells induction of CYP24A1 expression by
DAC seems to be independent of CYP24A1 promoter methyla-
tion (Höbaus et al., 2013a). Moreover, the methylation level of
the CYP24A1 promoter was comparably low both in colon ade-
nocarcinomas and the adjacent mucosa, although the expression
of CYP24A1 was significantly higher in the tumors (Höbaus et al.,
2013b).
Taken together, the regulation of CYP24A1 by DNA methyla-
tion appears to be tissue-dependent, both in health and disease.
CONCLUSIONS
There is a strong reciprocity between the vitamin D system and
epigenetic mechanisms. The vitamin D system is, on the one hand
regulated by epigenetic mechanisms and, on the other hand, is
involved in regulating epigenetic events. Critical vitamin D tool
genes can be silenced by DNA methylation. The VDR protein
interacts, directly or indirectly, with chromatin modifiers and
remodelers. Liganded VDR regulates expression of several of these
chromatin modifiers and remodelers, and it might even regulate
DNA methylation.
Epigenetic regulation of gene expression is a fine-tuned mech-
anism and its deregulation can lead to pathological conditions.
The impact of vitamin D in the maintenance of the normal epi-
genetic landscape underlines the central role of this hormone in
physiology.
PERSPECTIVES
One of the most fundamental questions in the control of gene
expression is the way how epigenetic marks are established,
erased, and recognized. Regulating epigenetic events could be
a further mechanism by which 1,25-D3 may prevent or delay
tumorigenesis and onset of chronic diseases. Therefore, we need
to understand better the impact of vitamin D on the epigenome,
and plan thorough and comprehensive studies to examine this
interplay.
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